| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalvista Pharmaceuticals, Inc. (KALV) has 12 insiders with recent SEC Form 4 filings, including 7 buys and 16 sells. KALV is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 462.6K | $12.49M | - | |
| Other | 223.5K | $6.03M | - | |
| Other | 142.5K | $3.85M | - | |
| Other | 100.0K | $2.70M | - | |
| Other | 51.4K | $1.39M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 19, 2018 | Svlsf Iv, LLC | 10% Owner | Sell | 2,136 | $20.02 | $42,758.45 | - | |
| Sep 10, 2018 | Oronsky Arnold L | Director | Buy | 58,824 | $17.00 | $1,000,008.00 | +17.8% | |
| Sep 10, 2018 | Cha Albert | Director | Buy | 1,058,824 | $17.00 | $18,000,008.00 | +352.6% | |
| Oct 12, 2017 | Ra Capital Management, LLC53 | Director, 10% Owner | Buy | 850,000 | $8.50 | $7,225,000.00 | +143.8% | |
| Oct 12, 2017 | Aldrich Richard | Director | Buy | 565,065 | $8.61 | $4,866,961.35 | +153.0% | |
| Oct 12, 2017 | Shah Rajeev M. | Director, 10% Owner | Buy | 850,000 | $8.50 | $7,225,000.00 | +143.8% | |
| Oct 12, 2017 | Novo Holdings A/s58 | 10% Owner | Sell | 2,725,283 | $9.64 | $26,271,181.80 | -15.1% | |
| Sep 15, 2017 | Novo Holdings A/s58 | 10% Owner | Sell | 176,647 | $7.21 | $1,273,979.75 | -1.6% | |
| Dec 30, 2015 | Renzi David | President &CEO | Sale+OE | 10,000 | $3.70 | $37,000.00 | -100% | |
| Apr 14, 2015 | Vivo Ventures Vi, LLC | 10% Owner | Buy | 1,012,500 | $5.00 | $5,062,500.00 | +13.7% |